Eli Lilly’s Innovation Statement: Advocat...

By HEOR Staff Writer

August 18, 2025

Eli Lilly has issued a statement advocating for US drug pricing reforms. It emphasizes maintaining America's leadership in biopharmaceutical innovation. The Eli Lilly innovation statement highlights a $50 billion US manufacturing investment since ...
Unlocking Self-Care South Africa: Strategies and Challenges in Healthcare Reform
Rare Medications Coverage in the Netherlands: Price Reductions Required
Strengthening the U.S. Pharmaceutical Supply Chain: Establishing a Strategic ...
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing
Urgent Care Effectiveness: Exploring Canadian Centre Models and Health System...
Enhancing Benefit Assessments: Insights from IQWiG Real-World Data Report
Donanemab Alzheimer’s Approval: A New Era in Treatment
Building a Better Ecosystem for Digitally Enabled Diabetes Care in Europe
Achieving International Drug Price Parity: Trump’s Mandate
Enhancing Patient Involvement in EU JCAs
NICE HealthTech Methods Update
Navigating Challenges for Small Countries to Access Innovative Medicines